![]() |
市场调查报告书
商品编码
1820452
2025 年至 2033 年化学资讯学市场规模、份额、趋势及按应用和地区分類的预测Chemoinformatics Market Size, Share, Trends and Forecast by Application, and Region, 2025-2033 |
2024 年全球化学资讯学市场规模为 68 亿美元。展望未来, IMARC Group估计到 2033 年市场规模将达到 131.2 亿美元,2025 年至 2033 年的复合年增长率为 7.58%。北美目前占据市场主导地位,2024 年市占率将超过 43.6%。全球市场受到以下因素的驱动:药物发现需求的不断增长、慢性病患病率的不断上升、人工智慧 (AI)、机器学习 (ML)、巨量资料分析的进步、个人化医疗需求的不断增长、研发 (R&D) 投资的增加、战略性产业合作以及製药、生物技术和学术研究领域的应用不断扩大。
全球化学资讯学市场的成长主要得益于对高效药物发现和开发流程日益增长的需求,而这又得益于个人化医疗需求的不断增长。此外,计算化学、机器学习和巨量资料分析领域的技术进步正在改善分子建模和虚拟筛选,并加快研究进度,从而促进市场发展。此外,製药和生技公司对研发计画的投入不断增加,也推动了市场成长。例如,根据行业报告,一项针对 130 多名生物技术高管的调查显示,60% 的生物技术公司打算增加研发支出,而只有 2% 的公司预计会削减支出。儘管受访者对产品的成功持乐观态度,但 32% 的受访者认为临床试验的复杂性是该领域面临的最大障碍。该报告还揭露了融资策略,48% 的受访者采用了製药合作伙伴关係,而 32% 的受访者采用了风险投资。因此,策略性外包和合作对于最大限度地促进临床开发和吸引投资都至关重要。政府针对创新医疗保健解决方案的倡议以及学术机构和行业参与者之间的合作正在进一步扩大化学资讯学工具的应用,从而促进全球市场扩张。
美国化学资讯学市场的需求是由药物发现和开发的持续进步所驱动的,而这种进步又受到个人化医疗和精准治疗需求成长的刺激。包括癌症和神经系统疾病在内的慢性病盛行率不断上升,迫使製药公司加快研究进程,增加了化学资讯工具的需求。例如,2024 年 3 月 14 日,《刺胳针神经病学》发表的一项研究报告称,2021 年全球有超过 30 亿人患有神经系统疾病。这些疾病已经超过所有其他原因,成为导致疾病和残疾的最大驱动因素,自 1990 年以来,目前导致相关的伤残调整生命年 (DALY) 增加了 18%。超过 80% 的神经系统死亡和健康损失发生在中低收入国家,从而引起人们对医疗保健取得的巨大不平等的关注。人工智慧和巨量资料分析的整合正在简化分子建模和化合物分析,这进一步推动了市场的成长。此外,政府支持数位医疗转型的措施和增加研发投资正在促进创新,从而扩大市场。
人工智慧和机器学习整合的成长
人工智慧 (AI) 与机器学习 (ML) 的融合正在加快化学研发活动的速度,并改变化学资讯学的市场趋势。产业报告显示,AI 和 ML 技术可将药物发现的时间缩短高达 50%,从而加快识别有用化合物所需的时间。用于预测分子特性等的 AI 模型使研究人员能够以前所未有的速度和精度模拟化学反应并分析资料。这可以透过最少的反覆试验来加快研究速度。事实证明,使用 AI 驱动的化学资讯学工具可以将研究相关成本降低约 40%,使其成为製药和学术研究机构急需的工具。这些进步也提高了药物发现和材料开发的效率,从而创新了新产品,并有可能催生医疗方法、材料和技术,从而推动该市场在未来几年的快速成长。
药物研发应用的兴起
化学资讯学正逐渐成为药物研发的关键领域之一,其工具越来越多地用于分析分子结构和预测生物活性。事实上,根据一份产业报告,超过75%的新药研发目前使用化学资讯学工具进行分子分析、化合物筛选和毒性预测。这一趋势使得过去五年药物研发中应用的计算方法成长了60%。这些工具能够预测分子相互作用并优化先导化合物,从而在更短的时间内识别出有潜力的候选药物。化学资讯学还可以透过减少昂贵且耗时的实验室实验来加快药物研发进程。随着数据驱动的药物研发发展,化学资讯学的需求将不断增长,从而为製药公司提供以最低成本进行高效药物研发的能力,确保患者获得更好的治疗效果,并提升化学资讯学的市场前景。
越来越多地采用基于云端的平台
云端平台正在改变研究机构和製药公司部署和使用化学资讯学工具的运作模式。据业界报告称,云端技术的采用加快了化学资料的处理速度。云端基础设施提供的灵活性和可扩展性使研究人员能够储存和处理大型资料集、促进远端协作,并可使用复杂的化学资讯学工具,而无需在现场建立大型基础设施。 Avaahi Tech 的 2024 年报告显示,製药公司透过采用云端服务平均降低了 30% 的 IT 营运成本,从而实现了更有效率、更具成本效益的研究和营运。一般来说,云端运算还支援跨学科更轻鬆的资料共享和协作,从而促进创新。随着云端平台的不断变化,它们在加速研究和实现药物开发突破方面发挥越来越重要的作用,尤其是在高通量环境中。
The global chemoinformatics market size was valued at USD 6.80 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 13.12 Billion by 2033, exhibiting a CAGR of 7.58% from 2025-2033. North America currently dominates the market, holding a significant market share of over 43.6% in 2024. The global market is driven by rising demand for drug discovery, increasing prevalence of chronic diseases, advancements in artificial intelligence (AI), machine learning (ML), big data analytics, growing need for personalized medicine, increased research and development (R&D) investments, strategic industry collaborations, and expanding applications in pharmaceutical, biotechnology, and academic research sectors.
The global chemoinformatics market growth is majorly driven by the increasing need for efficient drug discovery and development processes, fueled by rising demand for personalized medicine. Moreover, ongoing technological advancements in computational chemistry, ML, and big data analytics are improving molecular modeling and virtual screening, accelerating research timelines, thereby fostering the market. Additionally, growing investments from pharmaceutical and biotechnology companies into R&D initiatives are propelling market growth. For instance, as per industry reports, a survey of +130 biotech executives revealed that 60% of biotechs intend to increase their R&D spending, whereas only 2% expect cuts. Even though respondents were optimistic about the success of products, 32% named the complexity of clinical trials as the most significant obstacle in the segment. Funding strategies were also exposed in the report, and 48% used pharmaceutical partnerships while 32% used venture capital. Therefore, both strategic outsourcing and collaboration proved important to maximize clinical development and attract investment. Government initiatives for innovative healthcare solutions and collaborations between academic institutions and industry players are further expanding the adoption of chemoinformatics tools, which in turn is fostering market expansion globally.
The United States chemoinformatics market demand is driven by ongoing advancements in drug discovery and development spurred by the increase in demand for personalized medicine and precision therapeutics. A rising prevalence of chronic diseases, including cancers and neurological disorders, is compelling pharmaceutical companies to speed up the research processes that have increased the demand for chemoinformatics tools. For instance, on 14 March 2024, a study published in The Lancet Neurology reported that in 2021 more than 3 billion people worldwide were living with neurological conditions. The conditions have surpassed all other causes to become the largest driver of illness and disability and currently account for an increase of 18% more associated disability-adjusted life years (DALYs) since 1990. More than 80% of neurological deaths and health losses happen in low- and middle-income countries, thereby calling attention to major inequalities in accessing healthcare. Integration of AI and big data analytics is streamlining molecular modeling and compound analysis, which further propels the growth of the market. Furthermore, government initiatives supporting digital healthcare transformation and increased investments in R&D are fostering innovation, thereby expanding the market.
Growth in AI and Machine Learning Integration
The integration of AI and ML is enhancing the speed of chemical R&D activities, transforming the chemoinformatics market trends. Industrial reports show that AI and ML technology reduce the timeline of drug discovery by up to 50%, thereby accelerating how long it takes to identify useful compounds. AI models, such as those used to predict molecular properties, enable researchers to simulate chemical reactions and analyze data with unprecedented speed and accuracy. This leads to faster research through minimal trial and error. With AI-driven chemoinformatics tools, research has been proven to reduce the costs associated with it by about 40%, making it a much-needed tool for pharmaceutical and academic research institutions. These advancements are also improving the efficacy of drug discovery as well as material development, and thereby innovating new products, potentially giving rise to medical treatments, materials, and technology, thereby resulting in the rapid growth of this market in the coming years.
Rise in Drug Discovery Applications
Chemoinformatics is progressively becoming one of the key areas in drug discovery, with tools that are increasingly used in analyzing molecular structures and predicting biological activity. In fact, according to an industrial report, more than 75% of new drug discoveries now use the tools of chemoinformatics for molecular analysis, compound screening, and predictions of toxicity. This trend has made it increased by 60% to the computation methods applied in drug discovery in the last five years. These tools have the capability of identifying promising candidates for drugs with a much shorter period due to predictions in molecular interactions and optimization of lead compounds. Chemoinformatics also serves to speed up the drug development process by lessening the costly and time-consuming lab experiments involved. Further ahead with the data-driven evolvement of drug discovery, the role of chemoinformatics would be more in demand and growing, thereby providing pharmaceuticals the capacity for an efficient drug development process with minimal cost, ensuring a better outcome for patients and enhancing the chemoinformatics market outlook.
Increasing Adoption of Cloud-based Platforms
Cloud-based platforms are changing the mode of operation for chemoinformatics tool deployment and accessibility among research institutes and pharmaceutical firms. According to industrial reports, the adoption of cloud has quickened the processing of chemical data. The agility and scalability offered by cloud infrastructure enable researchers to store and process large datasets, facilitate collaboration from a distance, and avail complex chemoinformatics tools without needing a large infrastructure on-site. A 2024 report by Avaahi Tech reveals that pharmaceutical companies achieve an average 30% reduction in IT operational costs by adopting cloud services, enabling more efficient and cost-effective research and operations. Cloud computing, in general, also supports easier data sharing and collaboration across disciplines, thereby furthering innovation. As cloud-based platforms continue to change, they play an increasingly vital role in accelerating research and enabling breakthroughs in drug development, particularly in high-throughput environments.
The chemical analysis leads with around 30.0% of the chemoinformatics market share in 2024. It plays a very crucial role in drug discovery, material science, and quality control processes. This will be essential in developing new pharmaceuticals and chemical products as it accurately identifies, characterizes, and validates compounds. With increasing molecular structure complexity, demand for analytical tools and software will continue to rise to obtain more accurate data. In addition, pharmaceutical, agriculture, and environmental science industries greatly rely on chemical analysis for regulation and innovation purposes. Chemical analysis is being further dominated by these elements within the scope of chemoinformatics.
In 2024, North America accounted for the largest market share of over 43.6%. North America is the leader in the chemoinformatics market, as it has a strong pharmaceutical and biotechnology sector, which makes significant investments in drug discovery and development. Additionally, the rising incidence of chronic diseases and the growing demand for personalized medicine are propelling research efforts. Supportive policies from the government, strong investment in healthcare innovations, and mutual collaborations between research institutions and private players are driving North America's dominance in the chemoinformatics market.
United States Chemoinformatics Market Analysis
In 2024, the United States represented 83.60% of the North America passive electronic components market, driven by continual advancements in drug discovery as well as substantial investments in the research and development of chemoinformatics solutions. The fiscal year 2023 witnessed that the U.S. federal government spent about USD 190 Billion in R&D activities, thereby helping the widespread adaptation of chemoinformatics tools in pharmaceutical as well as in academic institutions. Integration of artificial intelligence and machine learning in chemoinformatics accelerates compound screening and molecular analysis. The leaders include BIOVIA and Schrodinger, offering software platforms that are useful for drug design and material sciences. Government support, through the National Institutes of Health (NIH) funding, improves innovation, and thus propels market growth. Apart from this, the home country software development bolster adds another layer of competitive advantage to US-based companies around the globe. The United States remains the top player in chemoinformatics, building upon export opportunities and collaborative alliances to strengthen this position.
Europe Chemoinformatics Market Analysis
Europe's chemoinformatics market is moving ahead due to the strict regulations and more pharmaceutical research. Horizon Europe has also granted EUR 95.5 Billion (USD 98.92 Billion) for research programs (2021-2027), and digital tools such as chemoinformatics are used in these drug developments. Germany, France, and the UK are first in using advanced software for molecular modeling, which is primarily due to their large pharmaceutical industries. ChemAxon and Cresset are companies working on new innovations, such as predictive analytics in chemical synthesis. The market is also benefited from the EU policy of open-access platforms for research, thereby creating a bridge between academia and industry. The drive for sustainable chemistry in Europe accelerates the growth of green tools, thereby accelerating the market further.
Asia Pacific Chemoinformatics Market Analysis
The Asia Pacific market is growing with increase in pharmaceutical R&D, as well as academic collaborations. To that extent, the Chinese Ministry of Science and Technology reported that in 2022, USD 441 Billion was allocated to R&D for innovations in drug discovery and computational chemistry. India, through its "Digital India" initiative, encourages the growth of indigenous software development, chemoinformatics thereby is gradually finding footholds in education and commerce. Local startups partner with international companies to advance AI-driven solutions for drug design. Japan and South Korea are also investing in supercomputing capabilities to enhance molecular simulations. The growing demand for precision medicine in the region further supports market expansion. Government-backed initiatives, such as China's AI Pharma program, ensure that the Asia Pacific remains a key player in the global chemoinformatics landscape.
Latin America Chemoinformatics Market Analysis
Advances in the pharmaceutical sector and research initiatives are the driving factors behind the growth of the Latin American chemoinformatics market. According to an industry report, in 2023, the Brazilian chemical and pharmaceutical industry achieved a turnover of EUR 105.2 Billion (USD 116.1 Billion), showing a strong potential of the region. Companies in Brazil are increasingly implementing chemoinformatics for improved drug discovery and development. In Mexico and Argentina, research institutions are including computational tools in their programs, further increasing the demand for advanced solutions. Government incentives, including tax benefits for R&D, are driving innovation. Besides, strategic collaboration with global players gives access to cutting-edge technologies, ensuring steady market growth. Moreover, the focus on combating neglected tropical diseases positions Latin America as an emerging contributor to the global chemoinformatics landscape.
Middle East and Africa Chemoinformatics Market Analysis
The Middle East and Africa market is expanding due to their investments in health care and research. In 2022, the Saudi Arabian Ministry of Investment reports that the Kingdom allocated USD 37 Billion to healthcare, which included programs for advanced pharmaceutical technologies. A regional leader in biotech research, South Africa becomes increasingly more encompassing using chemoinformatics technologies during its drug discovery processes. International ties provide access to cutting-edge technologies through partnerships with European software developers. The government programs promoting STEM education further add to the market potential. Furthermore, the increased focus on personalized medicine across the region increases the demand for predictive modeling and molecular docking tools, making the market a sustainable growth story.
The market for chemoinformatics is very competitive, with major companies emphasizing on advanced software solutions and platforms with artificial intelligence, machine learning, and big data analytics for streamlining drug discovery and molecular research. Continuous innovation fuels competition, making the firms heavily invest in R&D on developing even more accurate and efficient tools for molecular modeling, cheminformatics, and predictive analytics. Strategic partnerships, collaborations with academic institutions, and acquisitions are all common in order to improve their technological abilities and broaden market reach. The increasing need for personalized medicine and a rise in chronic diseases further enhance this dynamic competitive environment. For instance, On October 21, 2024, Agilent Technologies launched the Infinity III LC Series, featuring enhanced automation, connectivity, and sustainability capabilities. The new systems, including the 1290 Infinity III LC and 1260 Infinity III Prime LC, introduce InfinityLab Assist Technology to streamline operations and minimize errors. This innovation aims to improve lab efficiency, reduce operator workload, and provide greater accuracy through automated routines and advanced sample tracking, reinforcing Agilent's leadership in liquid chromatography solutions.